Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
August 10th 2022Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
Read More
What We’re Reading: Alzheimer Drug Setback; Rural Health Care Investment; Monkeypox Drug Delivery
August 10th 2022Acadia Pharmaceuticals’ pimavanserin (Nuplazid) was not extended by the FDA to include Alzheimer-related psychosis; HHS/Health Resources and Service Administration vow to strengthen rural health care; a new deal has the United States paying $26 million for Siga Technologies’ Tpoxx.
Read More
Heart Failure Prognosis Not Improved by Risk Score Prediction
August 10th 2022The REVEAL-HF study investigated using risk scores to improve patient outcomes through targeted interventions, including treatment initiation and intensity, end-of-life care, and hospitalization and mortality risks.
Read More
Reducing Health Care Disparities Starts at the Top, Says Dr Sachin Jain
August 10th 2022In this episode of Managed Care Cast, we speak with Sachin Jain, MD, MBA, SCAN Group and Health Plan's president and CEO, about how the organization made 10% of senior managers’ annual bonuses dependent on how well the gap in medication adherence among diverse populations was reduced.
Listen
CAR T Outcomes Not Significantly Affected by rrDLBCL Subgroup
August 9th 2022With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.
Read More
FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer
August 9th 2022Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Read More
Hepatitis C Reinfection Rates Low After Successful Treatment in People Who Inject Drugs
August 8th 2022Treatment of hepatitis C virus (HCV) with direct-acting antiviral medications was associated with low HCV reinfection rates among patients who inject drugs, although risk for reinfection was highest in the first 24 weeks of treatment and among those with ongoing injecting drug use.
Read More
Better Knowledge of EoE Results in Reduced Diagnostic Delay for European Patients
August 8th 2022European patients with eosinophilic esophagitis (EoE) had an improved diagnosis process and a faster diagnosis as new clinical practice guidelines were published over time, according to the results of a recent study.
Read More
Budget Bill Allowing Medicare to Negotiate Drug Prices Heads to House
August 8th 2022HR 5376, or the Inflation Reduction Act, is most significant piece of legislation affecting federal health policy since the passage of the Affordable Care Act in 2010; for Medicare beneficiaries, it caps insulin at $35 a month and includes other pricing reforms.
Read More
Only 7300 doses of the new Novavax vaccine have been administered with over 27 million Americans still unvaccinated; women in states where abortion is banned are managing abortions medically on their own outside of clinician care; affordable access to naloxone may become easier.
Read More
As Health Disparities “Weave Their Way Through Hypertension,” New Agents Are on the Way
August 8th 2022Coverage from the 2022 Congress of the American Society for Preventive Cardiology (ASPC) in Louisville, Kentucky, featuring 3 experts on aspects of hypertension treatment: Keith C. Ferdinand, MD, of Tulane University School of Medicine; Kim Allan Williams, MD, of the University of Louisville; and George C. Bakris, MD, of the University of Chicago Medicine.
Read More
Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
August 6th 2022The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive and HR-negative disease.
Read More
Young Adults With SCD Show Better Hydroxyurea Adherence Than Children, Adolescents
August 6th 2022With adherence estimated at less than 50% in children, adolescents, and young adults, a recent study stresses the importance of treatment adherence for patients with sickle cell disease receiving hydroxyurea and the benefit for those who do.
Read More